Recursion ו- Exscientia, שתי מובילות בתחום גילוי התרופות בתחום הבינה המלאכותית, התאחדו באופן רשמי כדי לקדם את התיעוש של גילוי תרופות

* Recursion חושפת פורטפוליו של טכנולוגיות חדישות שהבשילו למסחור עם יותר מ-10 תוכניות קליניות ופרה-קליניות, 10 תוכניות גילוי מתקדמות ויותר מ-10 תוכניות שותפות

*הפלטפורמה תתמקד בגילוי ופיתוח תרופות ראשונות והטובות מסוגן, ותדגים את היכולת למצוא תובנות חדשות ולהפחית באופן דרמטי את הזמן והעלות של הגילוי

* Recursion תארח שיחת עדכון היום, 20 בנובמבר 2024 בשעה 7:30 ET בבוקר / 5:30 MT בבוקר / 12:30 אחר הצהריים GMT בלינקדאין, X ויוטיוב

סולט לייק סיטי, 20 בנובמבר 2024 (GLOBE NEWSWIRE) –

השילוב העסקי של שתי חברות גילוי ופיתוח תרופות מבוססות בינה מלאכותית, Recursion (נאסד"ק: RXRX) ו-Exscientia הושלם, כאשר Exscientia הפכה לחברת בת בבעלות מלאה של Recursion היוצרת פלטפורמת גילוי תרופות משולבת אנכית ומאפשרת טכנולוגיה. Exscientia ADS (נאסד"ק: EXAI) הפסיקה להיסחר ותימחק מהמסחר בנאסד"ק.

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

• Recursion unveilspost-combination technology-enabled portfolio with more than 10 clinicaland preclinical programs, 10 advanced discovery programs, and more than 10partnered programs
• Platform willfocus on first and best-in-class drug discovery and development,demonstrating the ability to find novel insights and dramatically reducethe time and cost of discovery
• Recursion willhost an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m.MT / 12:30 p.m. GMT on LinkedIn, X and Youtube

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) –

The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (Nasdaq: EXAI) ceased trading and will be delisted from Nasdaq.

“I believe the combination of the incredible teams and platforms at Exscientia and Recursion position us as the leader of the AI-enabled drug discovery and development space,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “With more than 10 clinical and preclinical programs in the internal pipeline, more than 10 partnered programs and over $450M in upfront and realized milestone payments received from partners to date out of more than $20B possible, we are advancing a flywheel of discovery and creating value in our pipeline through technology.”

“The combination of our platforms and people make us the company to beat,” said David Hallett, Ph.D., former CSO and Interim CEO of Exscientia and newly appointed Chief Scientific Officer at Recursion. “With our combined strength of real-world proprietary data and the models we’ve created – hypothesizing, testing and learning in a continuous loop – we're redefining the space by shrinking timelines and costs, identifying and optimizing lead candidates faster than traditional methods.”

The Company is pleased to share updates on the combined entity’s pipeline, partnerships, and platform below:

Pipeline

The combined pipeline represents more than 10 clinical and preclinical programs. In addition there are approximately 10 advanced discovery programs in the current pipeline.

Updated guidance is bulleted below as well as a snapshot of our pipeline:

• REC-617 (CDK7inhibitor; Advanced Solid Tumors): Initial Phase 1 monotherapy safety andPK/PD data expected at the AACR Special Conference onDecember 9th 2024, and a webinar to follow on December 10th 2024.
• REV102 (ENPP1inhibitor; Hypophosphatasia): Development candidate nomination expected inQ4 2024
• REC-4881 (MEK1/2inhibitor, Familial Adenomatous Polyposis): Phase 1b/2 safety and earlyefficacy data expected in H1 2025
• REC-2282 (pan-HDACinhibitor; Neurofibromatosis Type 2): PFS6 futility analysis expected byH1 2025
• REC-3565 (MALT1inhibitor, B-Cell Malignancies): Phase 1 first patient dosed (FPD)expected in Q1 2025
• REC-4539 (LSD1inhibitor, Small-Cell Lung Cancer): Phase 1 first patient dosed (FPD)expected in H1 2025
• REC-994(Superoxide scavenger, Cerebral Cavernous Malformation): Further data tobe shared at an upcoming medical conference / publication / webinar in H12025; regulatory update expected by H2 2025
• REC-394 (C.difficile Toxin B selective inhibitor, C. difficile): Phase 2 updateexpected in Q1 2026
• REC-1245 (RBM39degrader; Solid Tumors and Lymphoma): Phase 1 dose-escalation data updateexpected in H1 2026
• REC-4209(undisclosed target; Idiopathic Pulmonary Fibrosis): IND-enabling studiesare ongoing
• REC-4881 inAPC/AXIN1 indications have been deprioritized as part of a disciplinedstrategic prioritization of the portfolio. Study status will be updatedon clinicaltrials.gov

Partnerships

The combined company’s therapeutic partnerships represent more than 10 partnered programs in areas such as oncology and immunology. The combined company has received approximately $450M in upfront and milestone payments from partnerships to date. Through these partnerships, we have the potential to receive more than approximately $20B in additional milestone payments before royalties.

Platform

With chemical design and synthesis methods from Exscientia and over 60 petabytes of proprietary data generated in house or licensed from partners like Helix and Tempus, the combined entity will strengthen the Recursion OS to be a first-in-class and best-in-class drug discovery and development platform.

The platform will continue to drive iterative loops of hypotheses and active learning all the way from research to development, with the goal of eventually creating virtual cells that will allow the company to execute clinical trials at scale.

Company, Board, and Leadership Updates

The combined company will have approximately 800 employees with the headquarters remaining in Salt Lake City, and primary offices in Toronto, Montreal, Milpitas, New York, the Oxford area, and London.

Individual board and executive leadership changes of Recursion, effective as of November 20, 2024, are summarized below:

• Franziska Michor,a former member of the Board of Directors of Exscientia, was appointed as aClass II Director of the Board of Directors of Recursion, with her initialterm to extend until the 2026 Annual Meeting of Stockholders of Recursion.
• Ben Taylor, formerChief Financial and Strategy Officer of Exscientia, was appointed as theChief Financial Officer of the Company and President of Recursion UK.
• Dave Hallett,former Interim Chief Executive Officer of Exscientia, was appointed asChief Scientific Officer of the Company.
• Kristen Rushton,Chief Business Operations Officer of the Company, was promoted to ChiefOperating Officer of the Company.
• Matthew Kinn,Senior Vice President, Business Development and Corporate Initiatives ofthe Company was promoted to serve as Chief Business Officer of theCompany.
• Lina Nilsson,Senior Vice President, Emerging Technologies of the Company, was promotedto serve on the executive team as Senior Vice President, Head of Platformof the Company.
• Michael Secora,Tina Marriott, and Laura Schaevitz will transition from their executiveroles into advisor roles for the combined company. All three have providedmany years of dedicated service to the Company and we wish to express ourheartfelt gratitude for each of them. Recursion would not be where it istoday without their dedication and efforts.

Update Call Information

Recursion will host an update call today at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT. The Company will broadcast the live stream from Recursion’s X (formerly Twitter), LinkedIn and YouTube accounts, and on Exscientia’s LinkedIn account. Questions can be submitted via this link ahead of time or during the livestream.

About Recursion

Recursion is a leading, clinical-stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale—up to millions of wet lab experiments weekly—and massive computational scale—owning and operating one of the most powerful supercomputers in the world—Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has other primary offices in Toronto, Montreal, the San Francisco Bay Area, New York, the Oxford area, and London.

Recursion Investor Relations
[email protected]

Recursion Media
[email protected]

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/359d7cd4-0ccf-4210-938d-f585a9b073ee
https://www.globenewswire.com/NewsRoom/AttachmentNg/a94dc301-518d-48a8-b8d3-430cd726d651
https://www.globenewswire.com/NewsRoom/AttachmentNg/57cb9454-a7a7-4abf-a76f-82356a3682ac

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire